Dr. Sulaiman Al Habib
سليمان الحبيبTechnical Analysis & Signals
Sulaiman Al Habib's stock shows an upward trend with positive signals in technical analysis.
Technical Analysis
The stock is currently trading at SAR 249.1, with the Relative Strength Index (RSI) at 54.5 indicating moderate momentum. The presence of a bullish divergence and ascending triangle pattern supports the likelihood of a continued upward trend.
Support & Resistance Levels
The main support level is at SAR 240.98, while resistance is at SAR 255.21. The stock is expected to react to these levels in the upcoming sessions.
Volume Analysis
Volume analysis indicates moderate trading activity, which may suggest investor interest in the stock. If trading volume continues to increase, it could reinforce the upward trend.
Fundamental Factors
The price-to-earnings (P/E) ratio stands at 36.3, indicating a relatively high valuation. Additionally, the dividend yield of 2.1% may attract income-seeking investors.
Risk Factors
The company may face market challenges, such as price volatility or changes in economic policies. Investors should be aware of these risks when making their decisions.
Recommendation
Disclaimer: This analysis is for educational purposes only and does not constitute investment advice. The stock is expected to continue its upward trend, but investors should conduct their own research.
Automated analysis is based on historical data and technical indicators and may not reflect future market conditions.
Financial Fundamentals
Price Data
Price Chart - Dr. Sulaiman Al Habib
4013Technical Analysis
Moving Averages
Momentum Indicators
Bollinger Bands
Within BandTrend Strength (ADX)
Moderate TrendFinancial Summary
Valuation
- Market Cap
- 87.18B
- P/E Ratio
- 36.30
- P/B Ratio
- 11.00
- EPS (Earnings/Share)
- 6.87
Profitability
- Revenue
- 13.71B
- Net Income
- 2.40B
- Return on Equity (ROE)
- +30.00%
- Shares Outstanding
- 350.00M
Balance Sheet
- Total Assets
- N/A
- Total Debt
- 9.30B
- Debt/Equity
- 1.10
- Free Float %
- +29.1%
Dividends & Margins
- Dividend Yield
- +2.10%
- Dividend/Share
- 5.24
- Book Value
- 22.65
Financial data extracted from published quarterly reports. All values in SAR unless otherwise stated.
Historical Financial Data
5 years| Year | Revenue | Net Income | Total Assets | Total Debt | EPS |
|---|---|---|---|---|---|
| 2025 | 13.71B +22.4% | 2.40B +3.7% | 23.20B +12.9% | 9.30B +14.0% | 6.86 +3.6% |
| 2024 | 11.20B +17.8% | 2.32B +13.2% | 20.56B +30.1% | 8.17B +57.5% | 6.62 +13.2% |
| 2023 | 9.51B +14.4% | 2.05B +23.9% | 15.80B +25.5% | 5.18B +47.2% | 5.85 +23.9% |
| 2022 | 8.31B | 1.65B | 12.58B | 3.52B | 4.72 |
| 2021 | — | — | — | — | — |
Historical data sourced from Yahoo Finance and may differ from official audited financial reports.
Price Forecast
These forecasts are based on technical analysis and AI and do not constitute investment advice. Past performance does not guarantee future results.
News & Events
Sulaiman Al Habib opens new medical centre in Riyadh
SNB Capital: TASI likely to trade between 10,000-11,700 pts in 2026
Sulaiman Al Habib to build 2 hospitals worth SAR 2B in Dammam, Riyadh
BSF Capital sets recommendation, TP for Sulaiman Al Habib
ANB Capital reviews Q4 2025 financials of four healthcare firms
Analysts weigh in on Sulaiman Al Habib Q4 2025 results
Sulaiman Al Habib Q4 2025: Financials, operating segment performance
Firms likely to declare cash dividends in Feb. based on historical pattern
News source: Argaam (argaam.com)
Sector Comparison
| Symbol | Name | Price | Change% |
|---|---|---|---|
| 4013 | Dr. Sulaiman Al Habib | 249.10 SAR | |
| 4002 | Mouwasat | 71.10 SAR | |
| 4004 | Dallah Healthcare | 124.60 SAR | |
| 4017 | Fakeeh Care | 32.40 SAR | |
| 4018 | Almoosa | 137.10 SAR | |
| 4005 | CARE | 130.70 SAR | |
| 4019 | SMC Healthcare | 17.70 SAR | |
| 4007 | Alhammadi | 25.72 SAR |
Dividend History
Dividend data from Tadawul records. All amounts in SAR. Estimated yield calculated based on year-end price.
Ownership Structure
Data source: Yahoo FinanceLast updated: 2026-03-26
Risk Assessment
Risk Factors
Average True Range 3.1% of stock price
Trading volume near or above average
P/E ratio 36.3 — above average
Debt-to-equity ratio 1.10
ADX indicator at 20
Stable fundamentals, low volatility, and good financial solvency
This assessment is automated based on quantitative data and does not constitute investment advice. Please consult a licensed financial advisor before making investment decisions.
FAQ
1 What is Dr. Sulaiman Al Habib stock price today?
Dr. Sulaiman Al Habib (4013) stock price today is 249.10 SAR, gaining by +0.04% compared to the previous session close. The 52-week price range is between 215.00 SAR and 285.25 SAR.
2 What is Dr. Sulaiman Al Habib stock valuation?
The automated analysis signal for Dr. Sulaiman Al Habib is "Buy" with 70% confidence. The P/E ratio is 36.3. The P/B ratio is 11.00.
3 Is Dr. Sulaiman Al Habib Shariah-compliant?
Yes, Dr. Sulaiman Al Habib (4013) is Shariah-compliant according to the latest lists approved by relevant Shariah authorities.
4 What are Dr. Sulaiman Al Habib dividend distributions?
Dr. Sulaiman Al Habib has a dividend yield of 2.10%, with an estimated annual dividend of 5.24 SAR per share.
5 What is Dr. Sulaiman Al Habib weekly performance?
Dr. Sulaiman Al Habib performance over different time periods: weekly change +0.48%, monthly -0.62%, and year-to-date -2.55%. The stock is currently trading with a volume of 148,621 shares.
6 What is the target level for Dr. Sulaiman Al Habib?
According to automated analysis for Dr. Sulaiman Al Habib: Short-term target (1-2 weeks): 255.00 SAR. Medium-term target (1-3 months): 265.00 SAR. Support level: 240.98 SAR. Resistance level: 255.21 SAR. Note: These are automated analytical levels and do not constitute investment advice.
Disclaimer
The information provided on this page is for educational and analytical purposes only and does not constitute investment advice or a recommendation to buy or sell. Past performance does not guarantee future results. All investments involve risk including loss of capital. Please consult a licensed financial advisor before making any investment decisions.
Automated analysis relies on historical data and technical indicators and may not reflect future market conditions.